



April 8, 2026

Senate Health & Human Services Committee
Colorado General Assembly

Re: HB 26-1262 – Colorado Patient Access and Compounding Clarity Act (OPPOSE)

Dear Chair Mullica, Vice Chair Jodeh and members of the committee:

We are writing on behalf of the Alliance for Safe Biologic Medicines (ASBM), an organization representing physicians, pharmacists, patient advocates, manufacturers and researchers committed to ensuring that patients have access to safe, effective, and properly regulated medicines.

We write to express our opposition to **HB 26-1262, the Colorado Patient Access and Compounding Clarity Act**. While compounded medications can play an important role for certain patients with individualized medical needs, this legislation would unnecessarily limit Colorado's ability to respond to emerging compounding-related risks and protect patient safety.

Compounding serves a legitimate purpose in circumstances such as drug shortages or when a patient requires a customized formulation not otherwise available. However, compounded drugs do not undergo the same premarket review for safety, effectiveness, quality, and manufacturing consistency as FDA-approved medicines. For that reason, strong state oversight remains essential.

HB 26-1262 is concerning because it would restrict Colorado's ability to adopt or enforce safeguards that go beyond the federal baseline. Federal law provides an important foundation, but it should be treated as a floor, rather than a ceiling for patient protection. States must retain the authority to respond when new risks emerge, business practices evolve, or enforcement gaps become apparent.

That flexibility is especially important today, as concerns continue to grow around mass compounding, inappropriate promotion, and the use of compounded drugs in settings that may lack adequate clinical and regulatory oversight. Colorado should not limit the ability of its Board of Pharmacy and other public health authorities to take reasonable action when needed to protect patients.

Patient access and patient safety are not in conflict. Colorado can preserve access to appropriate compounded medicines without weakening the state's longstanding authority to oversee pharmacy practice and address emerging threats to public health.

For these reasons, ASBM respectfully urges you to oppose **HB 26-1262**.


Sincerely,

Ralph McKibbin, MD FACP FACG AGAF
Chairman



Michael Reilly, Esq.

Executive Director, Alliance for Safe Biologic Medicines



Philip J Schneider MS FASHP FFIP

Advisory Board Chair

ASBM Steering Committee Members:

Alliance for Patient Access
American Academy of Dermatology
Autoimmune Association
Association of Clinical Research Organizations
Colon Cancer Alliance
Global Colon Cancer Association
Global Healthy Living Foundation
Health HIV
International Cancer Advocacy Network
Kidney Cancer Association
Lupus and Allied Diseases Association, Inc.
National Hispanic Medical Association
National Psoriasis Foundation
ZeroCancer